Literature DB >> 9218624

CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes.

R P Woitas1, M Lechmann, G Jung, R Kaiser, T Sauerbruch, U Spengler.   

Abstract

Since an efficient control of virus infections may depend on the appropriate lymphokine profile, we studied cytokine responses and CD30 induction, a recently proposed surrogate marker of type 2 cells, in 10 healthy anti-hepatitis C virus (HCV)-seropositive blood donors without viremia (group A) and in 15 patients with hepatitis C (group B). Intracytoplasmic IFN-gamma, IL-2, IL-4, and IL-10 were determined by triple-color flow cytometry in the CD3+ and CD3+/CD30+ lymphocyte subsets after stimulation of PBMC with rHCV core protein and five core-derived peptides corresponding to the four immunodominant Th epitopes C.T1 to C.T4. In group A, more type 1 cytokines were induced by the rHCV core protein and all immunodominant core peptides (p < 0.05), whereas IL-10-producing T cells were found more frequently in group B. Induction of CD30+ T cells was found almost exclusively in group B (p < 0.01). The difference in cytokine responses was due to the CD3+/CD30- T cell subset and not the CD3+/CD30+ subset, which predominantly produced both IL-10 and IFN-gamma, but only small amounts of IL-2 and IL-4. We conclude that immunodominant HCV core peptides induce preferentially type 1 cytokines in healthy anti-HCV-positive blood donors and CD30 expression in patients with chronic hepatitis C. However, in both groups, CD30+ T lymphocytes produce an intermediate Th0-like cytokine profile. Thus, chronicity in HCV infection may reflect a lack of type 1 cytokine production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218624

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism.

Authors:  Natalia Paladino; Hugo Fainboim; Graciela Theiler; Teresa Schroder; Alberto Eduardo Muñoz; Ana Claudia Flores; Omar Galdame; Leonardo Fainboim
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Does Fasciola hepatica infection modify the response of acute hepatitis C virus infection to IFN-alpha treatment?

Authors:  Mehmet Sahin; Mehmet Isler; Altug Senol; Mustafa Demirci; Zeynep Dilek Aydin
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels.

Authors:  R C Tam; K Ramasamy; J Bard; B Pai; C Lim; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.

Authors:  Ankur Goyal; P V Suneetha; G T Kumar; Deepak K Shukla; Naveen Arora; Shiv K Sarin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

5.  Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes.

Authors:  Anna R Ciccaglione; Emilia Stellacci; Cinzia Marcantonio; Valentina Muto; Michele Equestre; Giulia Marsili; Maria Rapicetta; Angela Battistini
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

6.  Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein.

Authors:  A Bergqvist; C M Rice
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses.

Authors:  Sara Sundström; Seisuke Ota; Lina Y Dimberg; Maria G Masucci; Anders Bergqvist
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C.

Authors:  Rainer P Woitas; Uwe Petersen; Dirk Moshage; Hans H Brackmann; Bertfried Matz; Tilman Sauerbruch; Ulrich Spengler
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

9.  Characterization of the specific CD4+ T cell response against the F protein during chronic hepatitis C virus infection.

Authors:  De-Yong Gao; Gen-Di Jin; Bi-Lian Yao; Dong-Hua Zhang; Lei-Lei Gu; Zhi-Meng Lu; Qiming Gong; Yu-Chun Lone; Qiang Deng; Xin-Xin Zhang
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

10.  Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection.

Authors:  Kazumoto Murata; Martin Lechmann; Ming Qiao; Toshiaki Gunji; Harvey J Alter; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.